BRAF and colorectal carcinoma: These patients tended to be older (median age, 67 years vs. 54.5 years among patients who had concordant results of IHC and genomic methods), had stage III (66.7% vs. 63.5%) or IV (33.3% vs. 18.8%) CRC, and had tumors enriched for BRAF p.V600E mutations (60% vs. 35.7%).